GOSS

Healthcare Biotechnology

Gossamer Bio, Inc.

$10.71

-0.06 -0.56% today

Price History

Not enough data

Key Stats

Market Cap

65.51M

Avg Volume

372,940

EPS

-$52.80

52W High

$309.60

52W Low

$9.12

Div. Yield

0.0%

Analyst Ratings

Hold

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-0.69

P/B Ratio

-55.78

P/S Ratio

1.23

EV/EBITDA

-0.31

EV/Revenue

0.91

Margins

Gross Margin 100.0%

Operating Margin (282.2%)

Net Margin (235.0%)

EBITDA Margin (297.6%)

Growth & Returns

Revenue Growth (YoY)

(19.6%)

Return on Assets

(62.4%)

Liquidity & Leverage

Current Ratio

0.53

Quick Ratio

0.46

Total Cash

57.03M

Total Debt

40.07M

About

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.